The effect of reperfusion on neuroprotection using an inhibitor of poly(ADP-ribose) polymerase

NeuroReport

Volumn 10, Issue 10, 1999, Pages 2017-2022

  Takahashi, Kazushi ^a   Greenberg, Joel H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

3 Aminobenzamide; Ischemia reperfusion injury; Laser Doppler flowmetry; Middle cerebral artery occlusion; Neuroprotection; Poly(ADP ribose polymerase; Rats

Indexed keywords

3 AMINOBENZAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; INTRAPERITONEAL DRUG ADMINISTRATION; LASER DOPPLER FLOWMETRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

EID: 0033551597     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199907130-00005     Document Type: Article

References (34)

1. Berger NA. Radiat Res 101, 4-15 (1985).
2. Szabo C and Dawson VL. Trends Pharmacol Sci 19, 287-298 (1998).
3. Zhang J, Dawson VL, Dawson TM and Snyder SH. Science 263, 687-689 (1994).
4. Szabo C, Zingarelli B, O'Connor M and Salzman AL. Proc Natl Acad Sci USA 93, 1753-1758 (1996).
5. Schraufstatter IU, Hyslop PA, Hinshaw DB et al. Proc Natl Acad Sci USA 83, 4908-4912 (1986).
6. Thies RL and Autor AP. Arch Biochem Biophys 286, 353-363 (1991).
7. Endres M, Scott G, Namura S et al. Neurosci Lett 248, 41-44 (1998).
8. Siesjo BK, Agardh CD and Bengtsson F. Cerebrovasc Brain Metab Rev 1, 165-211 (1989).
9. Cosi C, Suzuki H, Milani D et al. J Neurosci Res 39, 38-46 (1994).
10. Radons J, Hetler B, Burkie A et al. Biochem Biophys Res Commun 199, 1270-1277 (1994).
11. Takahashi K, Greenberg JH, Jackson P et al. J Cerebr Blood Flow Metab 17, 1137-1142 (1997).
12. Endres M, Wang ZQ, Namura S et al. J Cerebr Blood Flow Metab 17, 1143-1151 (1997).
13. Takahashi K, Pieper AA, Croul SE et al. Brain Res 829, 46-54 (1999).
14. Chen ST, Hsu CY, Hogan EL et al. Stroke 17, 738-743 (1986).
15. Swanson RA, Morton MT, Tsoo-Wu G et al. J Cerebr Blood Flow Metab 10, 290-293 (1990).
16. Kadoya C, Domino EF, Yang G-Y, et al. Stroke 26, 1035-1038 (1995).
17. Nelson CW, Wei EP, Povlishock JT et al. Am J Physiol 263, H1356-H1362 (1992).
18. Yip PK, He YY, Hsu CY et al. Neurology 41, 899-905 (1991).
19. Tokime T, Nozaki K, Sugino T et al. J Cerebr Blood Flow Metab 18, 991-997 (1998).
20. Cosi C, Chopin P and Marien M. Brain Res 735, 343-348 (1996).
21. Banasik M, Komura H, Shimoyama M and Ueda K. J Biol Chem 267, 1569-1575 (1992).
22. Milam KM and Cleaver JE. Science 223, 589-591 (1984).
23. Redegeld FA, Chatterjee S, Berger NA and Sitkovsky MV. J Immunol 149, 3509-3516 (1992).
24. Wilson GL, Patton NJ, McCord JM et al. Diabetologia 27, 587-591 (1984).
25. Hauschildt S, Scheipers P, Bessler WG and Mulsch A. Biochem J 288, 255-600 (1992).
26. Lo EH, Bosque-Hamilton P and Meng W. Stroke 29, 830-836 (1998).
27. Ayoub IA, Ogilvy CS and Maynard KI. Soc Neurosci Abstr 24, 214 (1998).
28. Lam TT. Res Commun Mol Pathol Pharmacol 95, 241-252 (1997).
29. Thiemermann C, Bowes J, Myint FP and Vane JR. Proc Natl Acad Sci USA 94, 679-683 (1997).
30. Zingarelli B, Cuzzocrea S, Zsengeller Z et al. Cardiovasc Res 36, 205-215 (1997).
31. Cuzzocrea S, Zingarelli B, Constantino G et al. Br J Pharmacol 121, 1065-1074 (1997).
32. Bowes J and Thiemermann C. Br J Pharmacol 124, 1254-1260 (1998).
33. Heller B, Wang ZQ, Wagner EF et al. J Biol Chem 270, 11176-11180 (1995).
34. Eliasson MJ, Sampei K, Mandir AS et al. Nature Med 3, 1089-1095 (1997).